Literature DB >> 22393531

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Paul S Aisen1, Jeffrey Cummings, Lon S Schneider.   

Abstract

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22393531      PMCID： PMC3282492          DOI： 10.1101/cshperspect.a006395

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN： 2157-1422            Impact factor:   6.915


  88 in total

1.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

Review 2.  Clinical trials in mild cognitive impairment: lessons for the future.

Authors:  V Jelic; M Kivipelto; B Winblad
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

3.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Authors:  K Ranga Rama Krishnan; H Cecil Charles; P Murali Doraiswamy; Jacobo Mintzer; Richard Weisler; Xin Yu; Carlos Perdomo; John R Ieni; Sharon Rogers
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

5.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

6.  Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.

Authors:  Rob McCarney; Peter Fisher; Steve Iliffe; Robbert van Haselen; Mark Griffin; Jan van der Meulen; James Warner
Journal:  Int J Geriatr Psychiatry       Date:  2008-12       Impact factor: 3.485

7.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Authors:  C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

8.  A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

Authors:  Christopher H van Dyck; Pierre N Tariot; Barnett Meyers; E Malca Resnick
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Apr-Jun       Impact factor: 2.703

Review 9.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

10.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study.

Authors:  Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp
Journal:  J Neurol       Date:  2009-08-04       Impact factor: 4.849
View more
  22 in total

Review 1.  Deciphering Alzheimer disease.

Authors:  Dennis Selkoe; Eckhard Mandelkow; David Holtzman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Guest editorial: Opportunities in rehabilitation research.

Authors:  Alexander K Ommaya; Kenneth M Adams; Richard M Allman; Eileen G Collins; Rory A Cooper; C Edward Dixon; Paul S Fishman; James A Henry; Randy Kardon; Robert D Kerns; Joel Kupersmith; Albert Lo; Richard Macko; Rachel McArdle; Regina E McGlinchey; Malcolm R McNeil; Thomas P O'Toole; P Hunter Peckham; Mark H Tuszynski; Stephen G Waxman; George F Wittenberg
Journal:  J Rehabil Res Dev       Date:  2013

3.  Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.

Authors:  Khaled H Elfakhri; Quoc-Viet Duong; Courtney Langley; Ashley Depaula; Youssef M Mousa; Trista Lebeouf; Courtney Cain; Amal Kaddoumi
Journal:  Neuroscience       Date:  2018-03-26       Impact factor: 3.590

Review 4.  Late-onset Alzheimer Disease.

Authors:  Gil D Rabinovici
Journal:  Continuum (Minneap Minn)       Date:  2019-02

Review 5.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

Review 6.  Epidemiology of Alzheimer disease.

Authors:  Richard Mayeux; Yaakov Stern
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

Review 7.  Recent Progress in the Pharmacotherapy of Alzheimer's Disease.

Authors:  Rita Khoury; Kush Patel; Jake Gold; Stephanie Hinds; George T Grossberg
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

Review 8.  Alzheimer disease in 2020.

Authors:  David M Holtzman; Eckhard Mandelkow; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

Review 9.  Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease.

Authors:  Lian-Feng Lin; Min-Jing Liao; Xiao-Yan Xue; Wei Zhang; Li Yan; Liang Cai; Xiao-Wen Zhou; Xing Zhou; Huan-Min Luo
Journal:  Neurosci Bull       Date:  2012-11-21       Impact factor: 5.203

10.  Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease.

Authors:  Rebecca Deering Brose; Elin Lehrmann; Yongqing Zhang; Roger H Reeves; Kirby D Smith; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2018-08-29       Impact factor: 4.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.